Figure 1.

Patient disposition in a group with epidermal growth factor receptor (EGFR)‐mutated lung adenocarcinoma and brain metastases (BM) treated with EGFR–tyrosine kinase inhibitor (TKI) alone or with whole‐brain radiotherapy (WBRT). ARMS, amplification mutation refractory system; ECOG, Eastern Cooperative Oncology Group.